

# Press Release

Regulated information

## ARSEUS DIVESTMENTS ON TRACK CHANGES IN BOARD OF DIRECTORS

Waregem (Belgium) / Rotterdam (Netherlands)<sup>1</sup>, 30 April 2014 – Arseus announced today that it has closed the divestments of Medical Universal and Eurotec. Arseus has sold Medical Universal to Soredex, part of PaloDEx Group Oy and Danaher Corporation (NYSE: DHR). Medical Universal, located in Lyon, imports and distributes imaging solutions in the French market. Arseus has sold Eurotec, specialized in the distribution of dental equipment in France, to the current management of the company. These divestments are another significant step for Arseus in divesting all of its remaining dental and medical activities before year end 2014.

The acquisitions in the United States and Europe, as announced in the press release of 7 February 2014, have been closed and finalized. Arseus will be able to integrate these acquisitions quickly and smoothly due to the quality of the organisation and its operational excellence.

Based on the recent changes in the shareholding structure, the following board members have resigned as members of the board of directors of Arseus NV:

- WPEF IV Holding Coöperatief WA, permanently represented by Frank Vluyen
- Supplyco BV, permanently represented by Cedric Van Cauwenbergh
- Enhold NV, permanently represented by De Wilde J Management BVBA, represented by Julien De Wilde
- Mylecke Management, Art & Invest NV, permanently represented by Marc Coucke

Arseus NV wishes to thank the board members most sincerely for their commitment, involvement and constructive contributions to the work of the board of directors. Potential replacements will be further considered in due course and, as the case may be, will be the subject of further announcements.

*In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.*

---

<sup>1</sup>This press release was sent out by Arseus NV and Arseus BV.

## **For more information:**

Marieke Palstra  
Director Investor Relations  
+31 88 33 11 213 (Office)  
[marieke.palstra@arseus.com](mailto:marieke.palstra@arseus.com)

## **Arseus profile**

Arseus is a R&D scientific company delivering innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into three divisions: Fagron is global market leader in pharmaceutical compounding. Corilus develops and supplies unique integrated ICT solutions with substantial added value to medical specialists and is market leader in Belgium, France and the Netherlands. HL Technology develops and produces innovative healthcare devices for the dental and medical markets. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.